TY - JOUR
T1 - Is a restaging TURBT necessary in high-risk NMIBC if the initial TURBT was performed with blue light?
AU - the Blue Light Cystoscopy with Cysview Registry Group
AU - Alsyouf, Muhannad
AU - Ladi-Seyedian, Seyedeh Sanam
AU - Konety, Badrinath
AU - Pohar, Kamal
AU - Holzbeierlein, Jeffrey M.
AU - Kates, Max
AU - Willard, Brian
AU - Taylor, Jennifer M.
AU - Liao, Joseph C.
AU - Kaimakliotis, Hristos Z.
AU - Porten, Sima P.
AU - Steinberg, Gary D.
AU - Tyson, Mark D.
AU - Lotan, Yair
AU - Daneshmand, Siamak
N1 - Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2023/2
Y1 - 2023/2
N2 - Objectives: To evaluate whether a restaging transurethral resection of bladder tumor (TURBT) is necessary in high-risk nonmuscle invasive bladder cancer (NMIBC) if the initial TURBT was performed using blue light (BL) technology. Methods and materials: Using the multi-institutional Cysview registry between 2014 and 2021, all consecutive adult patients with known NMIBC (Ta and T1 disease) who underwent TURBT followed by a restaging TURBT within 8 weeks were reviewed. Patients were stratified according to their initial TURBT, BL vs. white light (WL), and compared to determine rates of residual disease and upstaging. Univariate analysis was performed using Mann-Whitney U and chi-square tests, with P < 0.05 considered significant. Results: Overall, 115 patients had TURBT for NMIBC followed by a restaging TURBT within 8 weeks and were included in the analysis. Patients who underwent BL compared to WL for their initial TURBT had higher rates of benign pathology on restaging TURBT, although this was not statistically significant (47% vs. 30%; P = 0.08). Of patients with residual tumors on restaging TURBT, there were no differences in rates of Ta (22% vs. 26.5%; P = 0.62), T1 (22% vs. 26.5%; P = 0.62), or CIS (5.5% vs. 13%; P = 0.49) when the initial TURBT was done using BL compared to WL. Rates of upstaging to muscle invasive disease were also not different when initial TURBT was performed using BL compared to WL (3% vs. 4%; P = 0.78). Conclusions: TURBT using BL does not reduce rates of residual disease or risk of upstaging on restaging TURBT in Ta or T1 disease. Thus, a restaging TURBT is still necessary even if initial TURBT was performed using BL.
AB - Objectives: To evaluate whether a restaging transurethral resection of bladder tumor (TURBT) is necessary in high-risk nonmuscle invasive bladder cancer (NMIBC) if the initial TURBT was performed using blue light (BL) technology. Methods and materials: Using the multi-institutional Cysview registry between 2014 and 2021, all consecutive adult patients with known NMIBC (Ta and T1 disease) who underwent TURBT followed by a restaging TURBT within 8 weeks were reviewed. Patients were stratified according to their initial TURBT, BL vs. white light (WL), and compared to determine rates of residual disease and upstaging. Univariate analysis was performed using Mann-Whitney U and chi-square tests, with P < 0.05 considered significant. Results: Overall, 115 patients had TURBT for NMIBC followed by a restaging TURBT within 8 weeks and were included in the analysis. Patients who underwent BL compared to WL for their initial TURBT had higher rates of benign pathology on restaging TURBT, although this was not statistically significant (47% vs. 30%; P = 0.08). Of patients with residual tumors on restaging TURBT, there were no differences in rates of Ta (22% vs. 26.5%; P = 0.62), T1 (22% vs. 26.5%; P = 0.62), or CIS (5.5% vs. 13%; P = 0.49) when the initial TURBT was done using BL compared to WL. Rates of upstaging to muscle invasive disease were also not different when initial TURBT was performed using BL compared to WL (3% vs. 4%; P = 0.78). Conclusions: TURBT using BL does not reduce rates of residual disease or risk of upstaging on restaging TURBT in Ta or T1 disease. Thus, a restaging TURBT is still necessary even if initial TURBT was performed using BL.
KW - Bladder cancer
KW - Cystoscopy, Blue light
KW - Nonmuscle invasive bladder cancer
KW - Photodynamic diagnosis
KW - Transurethral resection of the bladder
UR - http://www.scopus.com/inward/record.url?scp=85142686820&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85142686820&partnerID=8YFLogxK
U2 - 10.1016/j.urolonc.2022.10.026
DO - 10.1016/j.urolonc.2022.10.026
M3 - Article
C2 - 36435710
AN - SCOPUS:85142686820
SN - 1078-1439
VL - 41
SP - 109.e9-109.e14
JO - Urologic Oncology: Seminars and Original Investigations
JF - Urologic Oncology: Seminars and Original Investigations
IS - 2
ER -